- Home
- CERO vs QNTM Comparison
CERO vs QNTM Comparison
Compare CERO & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- QNTM
- Stock Information
- Founded
- CERO 2017
- QNTM 1998
- Country
- CERO United States
- QNTM Canada
- Employees
- CERO N/A
- QNTM N/A
- Industry
- CERO
- QNTM
- Sector
- CERO
- QNTM
- Exchange
- CERO Nasdaq
- QNTM NYSE
- Market Cap
- CERO 8.4M
- QNTM 9.1M
- IPO Year
- CERO N/A
- QNTM N/A
- Fundamental
- Price
- CERO $2.34
- QNTM $3.42
- Analyst Decision
- CERO
- QNTM
- Analyst Count
- CERO 0
- QNTM 0
- Target Price
- CERO N/A
- QNTM N/A
- AVG Volume (30 Days)
- CERO 80.5M
- QNTM 223.5K
- Earning Date
- CERO 02-20-2025
- QNTM 01-28-2025
- Dividend Yield
- CERO N/A
- QNTM N/A
- EPS Growth
- CERO N/A
- QNTM N/A
- EPS
- CERO N/A
- QNTM N/A
- Revenue
- CERO N/A
- QNTM N/A
- Revenue This Year
- CERO N/A
- QNTM N/A
- Revenue Next Year
- CERO N/A
- QNTM N/A
- P/E Ratio
- CERO N/A
- QNTM N/A
- Revenue Growth
- CERO N/A
- QNTM N/A
- 52 Week Low
- CERO $2.22
- QNTM $2.70
- 52 Week High
- CERO $1,280.00
- QNTM $70.85
- Technical
- Relative Strength Index (RSI)
- CERO 32.54
- QNTM 41.28
- Support Level
- CERO $2.83
- QNTM $3.20
- Resistance Level
- CERO $3.50
- QNTM $3.55
- Average True Range (ATR)
- CERO 1.13
- QNTM 0.43
- MACD
- CERO 0.05
- QNTM -0.00
- Stochastic Oscillator
- CERO 1.43
- QNTM 14.97
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.